Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine
Abstract
Major depressive disorder (MDD) afflicts approximately 5 % of the world population, and about 30–50 % of patients who receive classical antidepressant medications do not achieve complete remission (treatment resistant depressive patients). Emerging evidence suggests that targeting opioid receptors mu (MOP), kappa (KOP), delta (DOP), and the nociceptin/orphanin FQ receptor (NOP) may yield effective therapeutics for stress-related psychiatric disorders. As depression and pain exhibit significant overlap in their clinical manifestations and molecular mechanisms involved, it is not a surprise that opioids, historically used to alleviate pain, emerged as promising and effective therapeutic options in the treatment of depression. The opioid signaling is dysregulated in depression and numerous preclinical studies and clinical trials strongly suggest that opioid modulation can serve as either an adjuvant or even an alternative to classical monoaminergic antidepressants. Importantly, some class...ical antidepressants require the opioid receptor modulation to exert their antidepressant effects. Finally, ketamine, a well-known anesthetic whose extremely efficient antidepressant effects were recently discovered, was shown to mediate its antidepressant effects via the endogenous opioid system. Thus, although opioid system modulation is a promising therapeutical venue in the treatment of depression further research is warranted to fully understand the benefits and weaknesses of such approach.
Keywords:
Antidepressants / Depression / DOP delta opioid receptor / Ketamine / KOP – kappa opioid receptor / MOP – mu opioid receptor / NOP – nociceptin/orphanin FQ receptorSource:
Life Sciences, 2023, 326, 121803-Funding / projects:
DOI: 10.1016/j.lfs.2023.121803
ISSN: 0024-3205
PubMed: 37245840
Scopus: 2-s2.0-85160749581
Institution/Community
VinčaTY - JOUR AU - Adžić, Miroslav AU - Lukić, Iva AU - Mitić, Miloš AU - Glavonić, Emilija AU - Dragićević, Nina AU - Ivković, Sanja PY - 2023 UR - https://vinar.vin.bg.ac.rs/handle/123456789/11044 AB - Major depressive disorder (MDD) afflicts approximately 5 % of the world population, and about 30–50 % of patients who receive classical antidepressant medications do not achieve complete remission (treatment resistant depressive patients). Emerging evidence suggests that targeting opioid receptors mu (MOP), kappa (KOP), delta (DOP), and the nociceptin/orphanin FQ receptor (NOP) may yield effective therapeutics for stress-related psychiatric disorders. As depression and pain exhibit significant overlap in their clinical manifestations and molecular mechanisms involved, it is not a surprise that opioids, historically used to alleviate pain, emerged as promising and effective therapeutic options in the treatment of depression. The opioid signaling is dysregulated in depression and numerous preclinical studies and clinical trials strongly suggest that opioid modulation can serve as either an adjuvant or even an alternative to classical monoaminergic antidepressants. Importantly, some classical antidepressants require the opioid receptor modulation to exert their antidepressant effects. Finally, ketamine, a well-known anesthetic whose extremely efficient antidepressant effects were recently discovered, was shown to mediate its antidepressant effects via the endogenous opioid system. Thus, although opioid system modulation is a promising therapeutical venue in the treatment of depression further research is warranted to fully understand the benefits and weaknesses of such approach. T2 - Life Sciences T2 - Life SciencesLife Sciences T1 - Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine VL - 326 SP - 121803 DO - 10.1016/j.lfs.2023.121803 ER -
@article{ author = "Adžić, Miroslav and Lukić, Iva and Mitić, Miloš and Glavonić, Emilija and Dragićević, Nina and Ivković, Sanja", year = "2023", abstract = "Major depressive disorder (MDD) afflicts approximately 5 % of the world population, and about 30–50 % of patients who receive classical antidepressant medications do not achieve complete remission (treatment resistant depressive patients). Emerging evidence suggests that targeting opioid receptors mu (MOP), kappa (KOP), delta (DOP), and the nociceptin/orphanin FQ receptor (NOP) may yield effective therapeutics for stress-related psychiatric disorders. As depression and pain exhibit significant overlap in their clinical manifestations and molecular mechanisms involved, it is not a surprise that opioids, historically used to alleviate pain, emerged as promising and effective therapeutic options in the treatment of depression. The opioid signaling is dysregulated in depression and numerous preclinical studies and clinical trials strongly suggest that opioid modulation can serve as either an adjuvant or even an alternative to classical monoaminergic antidepressants. Importantly, some classical antidepressants require the opioid receptor modulation to exert their antidepressant effects. Finally, ketamine, a well-known anesthetic whose extremely efficient antidepressant effects were recently discovered, was shown to mediate its antidepressant effects via the endogenous opioid system. Thus, although opioid system modulation is a promising therapeutical venue in the treatment of depression further research is warranted to fully understand the benefits and weaknesses of such approach.", journal = "Life Sciences, Life SciencesLife Sciences", title = "Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine", volume = "326", pages = "121803", doi = "10.1016/j.lfs.2023.121803" }
Adžić, M., Lukić, I., Mitić, M., Glavonić, E., Dragićević, N.,& Ivković, S.. (2023). Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. in Life Sciences, 326, 121803. https://doi.org/10.1016/j.lfs.2023.121803
Adžić M, Lukić I, Mitić M, Glavonić E, Dragićević N, Ivković S. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. in Life Sciences. 2023;326:121803. doi:10.1016/j.lfs.2023.121803 .
Adžić, Miroslav, Lukić, Iva, Mitić, Miloš, Glavonić, Emilija, Dragićević, Nina, Ivković, Sanja, "Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine" in Life Sciences, 326 (2023):121803, https://doi.org/10.1016/j.lfs.2023.121803 . .